Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended
Executive Summary
Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment
You may also be interested in...
Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges
Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.
Emend Risk Program To Ensure Prescribers Understand Approved Indication
Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications
Pharmacia Somavert Manufacturing Changes Planned For U.S. Approval
Pharmacia expects FDA approval of the acromegaly drug Somavert (pegvisomant) in the "next several months" pending clearance of a revised manufacturing process